Lucia (@luciaphl) — Bluesky Profile

3 months ago

Omadacycline versus moxifloxacin for community-acquired bacterial #pneumonia (OPTIC-2): a phase 3b RCT

Demonstrates the safety and efficacy of omadacycline in CABP

www.thelancet.com/journals/ecl...
#CAP #CABP #MedSky

1 1 0 0

9 months ago

It really is… a true nightmare.

1 0 0 0

9 months ago

5 1 0 0

11 months ago

Check out the work from Dr. @seanpharmd.bsky.social & team on real-world experience of omadacycline for enterococcal infections at #ESCMIDGlobal 2025! 💊

Among hospitalized pts with enterococcal infections, omadacycline demonstrated high clinical success and low 30-day mortality (11%)!

2 4 0 0

11 months ago

Evaluation of omadacycline in vitro activity against Corynebacterium species ABSTRACTCorynebacterium spp. are gram-positive bacteria increasingly recognized as pathogens. This study evaluates the MICs of omadacycline, a tetracycline, against 40 clinical Corynebacterium isolates using two methodologies: broth microdilution (BMD) and Liofilchem omadacycline MIC Test Strip (MTS). By BMD, the MIC50, MIC90, and MIC range were 0.5 µg/mL, 1 µg/mL, and 0.12–2.0 µg/mL, respectively. Comparing BMD to MTS, essential agreement (EA, within ±1 doubling dilution of the reference BMD MIC) was 87.5% (95% CI: 73.0%–95.4%).

Corynebacterium spp. are emerging pathogens. Omadacycline MICs for 40 isolates: MIC50 0.5 µg/mL, MIC90 1 µg/mL, range 0.12–2.0 µg/mL. EA between BMD & MTS was 87.5% (95% CI: 73.0%–95.4%).

#idsky

0 1 0 0

1 year ago

It’s truly dystopian. Evil, greed, ignorance…

1 0 0 0